We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00446940
First Posted: March 13, 2007
Last Update Posted: September 9, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bader, Ted, M.D.
  Purpose
Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.

Condition Intervention Phase
Hepatitis C Drug: rosuvastatin Drug: atorvastatin Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

Resource links provided by NLM:


Further study details as provided by Bader, Ted, M.D.:

Estimated Enrollment: 16
Study Start Date: December 2006
Study Completion Date: March 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hepatitis C

Exclusion Criteria:

  • HIV positivity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00446940


Locations
United States, Oklahoma
VA Hospital
OKlahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Bader, Ted, M.D.
Investigators
Principal Investigator: Ted Bader, MD VA Medical Center, Oklahoma City, OK
  More Information

ClinicalTrials.gov Identifier: NCT00446940     History of Changes
Other Study ID Numbers: 13133
First Submitted: March 11, 2007
First Posted: March 13, 2007
Last Update Posted: September 9, 2008
Last Verified: September 2008

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Atorvastatin Calcium
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors